The renin-angiotensin and the kallikrein-kinin systems

被引:106
作者
Campbell, DJ
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
关键词
angiotensin; bradykinin; kallidin; kallikrein; kininogen; kallistatin;
D O I
10.1016/S1357-2725(02)00262-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS) each encompasses a large number of molecules, with several participating in both systems. The RAS generates a family of bioactive angiotensin peptides with varying biological activities. These include angiotensin-(1-8) (An-II), angiotensin-(2-8) (Ang III), angiotensin-(3-8) (Ang IV), and angiotensin-(1-7) [Ang-(1 -7)]. An-II and Ang III act on type 1 (AT(1)) and type 2 (AT(2)) angiotensin receptors, whereas, Ang IV and Ang-(1-7) act on their own receptors. The KKS also generates a family of bioactive peptides with varying biological activities. These include hydroxylated and non-hydroxylated bradykinin and kallidin peptides and their carboxypeptidase metabolites des-Arg(9)-bradykinin and des-Arg(10)-kallidin. Whereas bradykinin and kallidin act mainly viathe type 2 bradykinin (B-2) receptor, des-Arg(9)-bradykinin and des-Arg(10)-kallidin act mainly via the type 1 bradykinin (B-1) receptor. The AT(1) receptor forms heterodimers with the AT(2) and B-2 receptors and there is cross talk between the AT(1) and epidermal growth factor receptors. The B-2 receptor also interacts with angiotensin converting enzyme and nitric oxide synthase. Both angiotensin and kinin peptides are metabolised by many different peptidases that are important determinants of the activities of the RAS and KKS, and several of which participate in both systems. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 32 条
[11]   Targeting kinin B1 receptor for therapeutic neovascularization [J].
Emanueli, C ;
Salis, MB ;
Stacca, T ;
Pintus, G ;
Kirchmair, R ;
Isner, JM ;
Pinna, A ;
Gaspa, L ;
Regoli, D ;
Cayla, C ;
Pesquero, JB ;
Bader, M ;
Madeddu, P .
CIRCULATION, 2002, 105 (03) :360-366
[12]   Angiotensin-(1-7): Cardioprotective effect in myocardial ischemia/reperfusion [J].
Ferreira, AJ ;
Santos, RAS ;
Almeida, AP .
HYPERTENSION, 2001, 38 (03) :665-668
[13]   Human bradykinin B2 receptor is activated by kallikrein and other serine proteases [J].
Hecquet, C ;
Tan, FL ;
Marcic, BM ;
Erdös, EG .
MOLECULAR PHARMACOLOGY, 2000, 58 (04) :828-836
[14]   Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase [J].
Ju, H ;
Venema, VJ ;
Marrero, MB ;
Venema, RC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (37) :24025-24029
[15]   Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense [J].
Kagiyama, S ;
Eguchi, S ;
Frank, GD ;
Inagami, T ;
Zhang, YC ;
Phillips, MI .
CIRCULATION, 2002, 106 (08) :909-912
[16]   AT2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions [J].
Katada, J ;
Majima, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (04) :484-491
[17]   Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - Role of kinins and angiotensin II type 2 receptors [J].
Liu, YH ;
Yang, XP ;
Sharov, VG ;
Nass, O ;
Sabbah, HN ;
Peterson, E ;
Carretero, OA .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (08) :1926-1935
[18]  
Marcic BM, 2000, J PHARMACOL EXP THER, V294, P605
[19]   Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation [J].
Niimura, F ;
Labosky, PA ;
Kakuchi, J ;
Okubo, S ;
Yoshida, H ;
Oikawa, T ;
Ichiki, T ;
Naftilan, AJ ;
Fogo, A ;
Inagami, T ;
Hogan, BLM ;
Ichikawa, I .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2947-2954
[20]   Plasma bradykinin in angio-oedema [J].
Nussberger, J ;
Cugno, M ;
Amstutz, C ;
Cicardi, M ;
Pellacani, A ;
Agostoni, A .
LANCET, 1998, 351 (9117) :1693-1697